Navigation Links
Dr. Abraham Abuchowski of Prolong Pharmaceuticals Honored With Inaugural Tibbetts Award by the U.S. Small Business Administration
Date:2/17/2011

SOUTH PLAINFIELD, N.J., Feb. 17, 2011 /PRNewswire/ -- Dr. Abraham Abuchowski, CEO and Scientific Founder of Prolong Pharmaceuticals, was honored by the U.S. Small Business Administration on February 15 with their inaugural Tibbetts Award for leadership in innovation and job creation. Dr. Abuchowski was one of eight individuals recognized, and the only honoree in the pharmaceutical/biopharmaceutical industry.

Dr. Abuchowski was the originator of the PEGylation technology, now the most widely-used protein drug delivery system in the world. Prior to being one of the founders of Prolong Pharmaceuticals, Dr. Abuchowski founded Enzon Pharmaceuticals, now a fully integrated, publicly-traded company. During his time as CEO Enzon successfully introduced the PEGylation technology and brought three new protein-based drugs to market with FDA approval. PEGylated drugs have garnered sales in the tens of billions of dollars around the world.

The Tibbetts Award winners were honored for the critical role they play in research and development for the government and for their success in driving innovation and creating new jobs. "Winning the future requires redoubling our commitment to supporting innovative entrepreneurs like those we honor with Tibbetts Awards," said Karen Mills, SBA administrator. "Their stories illustrate the promise of the new generation of innovative entrepreneurs and remind us all how central the success of one high growth small business can be to our competitiveness as a nation."

About Prolong Pharmaceuticals

Headquartered in South Plainfield, New Jersey, Prolong Pharmaceuticals, LLC is developing biopharmaceutical products targeting the treatment of anemia resulting from an oxygen deficiency. First founded in 2002 as a research company, Prolong is focused on sickle cell anemia, diabetic ischemia, and several trauma indications. The company's senior management team includes inventors of the most successful drug delivery technology in pharmaceutical history, PEGylation, now responsible for more than $30 billion in drug sales worldwide. For more information visit: www.prolongpharmaceuticals.com


'/>"/>
SOURCE Prolong Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Prolong Pharmaceuticals Leases 24,000-Square-Foot Manufacturing Facility, Adds Facilities Veteran to Executive Team
2. Prolong Pharmaceuticals Boosts Executive Team
3. Prolong Pharmaceuticals Secures $30 Million in Funding
4. Prolong Pharmaceuticals Names Industry Veteran Glenn Kazo President
5. Updated Results from Phase 2 Trial Demonstrate Prolonged Hematologic Relapse-Free Survival of Micromets Blinatumomab in Patients with Acute Lymphoblastic Leukemia
6. Trauma 411: Prolonged Surgery Should be Avoided in Certain Cases
7. Investigational Cancer Drug BSI-201 Showed Clinical Benefit in 62% of Patients with Triple-Negative Metastatic Breast Cancer and Significantly Prolonged Survival
8. Prostate Cancer Immunotherapy Significantly Prolongs Survival in Men With Advanced Prostate Cancer
9. Data Presented at AUA Demonstrate PROVENGE Significantly Prolongs Survival for Men With Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study
10. Prolonged Progression-Free Survival Demonstrated by VELCADE(R) (Bortezomib) for Injection Based Induction Regimens in Transplant-Eligible Previously Untreated Multiple Myeloma Patients
11. Nebulized Perforomist(TM) Inhalation Solution Provided Prolonged Bronchodilation and Increased Patient Satisfaction Compared to Albuterol/Ipratropium MDI
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/7/2017)... -- Endo International plc (NASDAQ: ENDP ) ... Joseph R. Goodwin , U.S. District Court Judge for ... , entered a case management order in MDL 2325, ... Litigation (the "MDL") that includes a provision requiring plaintiffs ... on specific causation within one hundred twenty (120) days ...
(Date:6/3/2017)... -- Eli Lilly and Company (NYSE: LLY ... 3 MONARCH 2 study showed that abemaciclib, a ... with fulvestrant, significantly improved progression-free survival (PFS) compared ... hormone-receptor-positive (HR+), human epidermal growth factor receptor 2-negative ... progressed after endocrine therapy (median PFS, 16.4 vs. ...
(Date:5/30/2017)... AVIV, Israel , May 30, 2017 ... stage pharmaceutical Company specializing in the development of ... will present a company overview at three upcoming ... The 7th Annual LD Micro Invitational: ... Date:                     ...
Breaking Medicine Technology:
(Date:6/26/2017)... ... ... Center is now offering various types of dental implants to restore lost teeth. Dental implants ... such as crowns, bridges, or dentures. An implant is placed directly into the jawbone where ... tooth. , Several types of dental implants are available, including: , ...
(Date:6/26/2017)... ... June 26, 2017 , ... The Centers for ... the hiring of Richard Robinson as chief operating officer (COO). In this role, ... a proven track record of simplifying business processes and developing growth strategies to ...
(Date:6/26/2017)... ... June 26, 2017 , ... ... leakage is revolutionizing the way women look and feel about themselves and their ... of female sexual dysfunction and urinary leakage head on with a ground breaking ...
(Date:6/26/2017)... , ... June 26, 2017 , ... ... staff, and consumers are seeing lots of red these days. According to recent ... charges that result from medical coding errors(1). Some studies point to Electronic Health ...
(Date:6/26/2017)... ... June 26, 2017 , ... New patients with ... Angela Cotey, with or without a referral. Dr. Cotey is a trusted dentist who ... preferred tooth replacement option. , Patients with missing teeth in Fitchburg, WI, are encouraged ...
Breaking Medicine News(10 mins):